Product Images Tadalafil

This is a tablet medicine containing Tadalafil USP 20mg, produced by L' PHARMACEUTICALS INCORPORATED®. There are 15 tablets per container and the product code is 43063-969-15. The medicine is indicated for use as directed, with possible side effects. The medicine should be taken orally, with the suggested dosing specified. The FDA can be contacted to report side effects or for medical advice. The product has an expiration date of March 2022 and a lot number of G20E13. The tablet is oval in shape and coated with a film layer.*

This is a graph (Figure 1) showing the mean maximal change in blood pressure in response to sublingual nitroglycerin at different time intervals after administering tadalafil (20mg) or placebo. The x-axis shows the time in hours and the y-axis shows the difference in blood pressure in mmHg. The graph also shows the standing and supine systolic and diastolic blood pressure readings.*

This is a description of a study involving the combination of Tadalfil (20 mg) and Doxazosin (8 mg) versus a placebo with Dorazosin (8 mg). The study measured the mean change from baseline in systolic blood pressure in a supine position, as shown in Figure 2.*

The text describes the dosages of two medications used in a study: 20mg of tadalafil and 8 mg of doxazosin, with a comparison to a placebo. The study measured changes in systolic blood pressure over time after administration of the medication or placebo.*

This is a graph that shows the plasma tadalafil concentrations over time. It displays the mean and standard deviation of plasma tadalafil levels after the administration of a single 20mg dose and multiple 5mg doses of tadalafil per day. The x-axis shows the time in hours, whereas the y-axis shows the concentration of tadalafil in plasma (mg/L).*

This appears to be a graph or chart related to a study on the effects of Tatalafil 5mg on BPH (Benign Prostatic Hyperplasia) patients. The graph shows the change from baseline in IPSS (International Prostate Symptom Score) total score over the duration of treatment in weeks, with Tatalafil and placebo being compared. However, without more context or information, it is difficult to provide a more specific description or analysis.*

The text describes a figure labeled "Figure 7" that shows the mean total IPSS changes by visit in BPH patients taking Tadalafil for once daily use together with Finasteride. The figure shows four weeks of therapy, with data represented at the 0, 4, 12, and 26-week marks. The data compares Tadalafil and Finasteride treatments against a placebo/Finasteride treatment. The text provides LS Mean Change from Baseline and Least-Squares Treatment Difference values, as well as significance levels of p<0.001 and p<0.05.*